Phase 3 · NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- ClinicalTrials.gov ID
- NCT06260722
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 1,250
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Semaglutide
- Comparator
- Not reported
- Eligible ages
- 18 Years – No maximum
- Locations
- 77 sites · Argentina, Canada, Mexico, Puerto Rico, United States
- Study start
- 21 Feb 2024
- Primary completion
- 27 Aug 2026
- Study completion
- 1 Feb 2027
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 28 Sept 2026
Endpoints
Primary
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Secondary
Change from Baseline in HbA1c (%); Percentage of Participants Who Achieve HbA1c ≤ 6.5%; Percentage of Participants Who Achieve HbA1c < 5.7%; Percent Change from Baseline in Body Weight; Change from Baseline in Body Weight; Percentage of Participants Who Achieve Weight Reduction of ≥ 5%; Percentage of Participants Who Achieve Weight Reduction of ≥ 10%; Percentage of Participants Who Achieve Weight Reduction of ≥ 15%; Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight Reduction; Percent Change from Baseline in Triglycerides; Percent Change from Baseline in Non- high-density lipoprotein (HDL) Cholesterol; Change from Baseline in Systolic Blood Pressure (SBP)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Primary completion date | 2026-08-01→2026-08-27 | 29 Sept 2026 | ClinicalTrials.gov |
| Study completion date | 2027-01-01→2027-02-01 | 29 Sept 2026 | ClinicalTrials.gov |